BioLine Rx Ltd (NASDAQ:BLRX) Launch Phase 3 Trial To Assess BL-8040 Effect On Blood Stem Cells

BioLine Rx Ltd (NASDAQ:BLRX) recently launched a Phase 3 trial to find out if the outflux of blood stem cells from bone marrow can improve by adding BL-8040 to standard treatment before a stem cell transplant is conducted in the case of multiple myeloma. The company had made an announcement regarding its intention to advance the treatment in Phase 3 last year in August.

The Chief of the Division Of Oncology at the Washington University School of Medicine, John F. Dipersio, MD, said in the press release that he is very excited to test the role of BL-8040 which is a novel CXCR4 inhibitor with G-CSF for the mobilization of peripheral blood stems cells derived from the patients undergoing autologous transplant for multiple myeloma.

DiPersio said that he was extremely hopeful that this new development will provide yet another approach to the optimal hematopoietic stem cell collection in this challenging group of patients. Incidentally, DiPersio is also working as the lead investigator of this blood stem cells study. Prior to setting up the study, BioLine obtained regulatory approval from the concerned authorities.

However, the study is yet to recruit participants.

BioLine Hopes BL-8040 Will Make Myeloma Treatment More Efficient

Blood stem cell transplants are the basis of any myeloma treatment. In this process, the bone marrow stem cells of the patients are used. Currently, healthcare experts are using a compound called granulocyte colony-stimulating factor (G-CSF) to attract stem cells from the bone marrow so that blood can be harvested from them.

However, BioLine is of the belief that its compound BL-8040 can make this blood harvesting process more efficient. In the Phase 3 trial known as GENESIS, the researchers will be comparing the combination of G-CSF and BL-8040 to G-CSF and a placebo. The researchers are trying to measure if it is possible to harvest more stem cells using the above combination as compared to G-CSF alone.

To evaluate the efficacy of this combination, the patients will be given only one dose of BL-8040 and then the researchers will employ a special procedure called apheresis to gather stem cells twice.

Abbott Michael

Abbott Michael

Michael joined US Markets Daily in 2009 and is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments.